Having trouble accessing articles? Reset your cache.

Napabucasin: Additional Phase Ib/II data

Data from a cohort of 27 patients with non-small cell lung cancer (NSCLC) in the open-label, North American Phase Ib/II BBI608-201 trial showed that twice-daily oral napabucasin, starting at a dose of

Read the full 326 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE